O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

Publication date

2021-03-19

Authors

Verboom, Diana M
Varkila, Meri R J
Morrow, B
Davies, T
Ibarra de Palacios, P
Poolman, J
Hermans, Peter
Dudley, E G
Roberts, E
Cremer, Olaf LORCID 0000-0003-4264-1108ISNI 0000000387039874

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. METHODS: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

Keywords

Bloodstream infections, Escherichia coli, ExPEC, ICU, Vaccine, General Veterinary, Public Health, Environmental and Occupational Health, Infectious Diseases, Molecular Medicine, General Immunology and Microbiology, Journal Article

Citation

Verboom, D M, Varkila, M R J, Morrow, B, Davies, T, Ibarra de Palacios, P, Poolman, J, Hermans, P W M, Dudley, E G, Roberts, E, Cremer, O L & Bonten, M J M 2021, 'O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands', Vaccine, vol. 39, no. 12, pp. 1670-1674. https://doi.org/10.1016/j.vaccine.2021.02.031